Quick Answer
Theravance Biopharma, Inc. reported Operating Income of -$3.60 million for fiscal year 2025.
Theravance Biopharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$3.60M | +92.3% |
| 2024 | -$46.95M | +16.2% |
| 2023 | -$56.03M | +39.1% |
| 2022 | -$91.96M | +64.3% |
| 2021 | -$257.78M | +13.4% |
| 2020 | -$297.63M | -18.1% |
| 2019 | -$251.91M | -5.5% |
| 2018 | -$238.75M | +8.2% |
| 2017 | -$260.12M | -44.1% |
| 2016 | -$180.47M | +0.8% |
| 2015 | -$181.90M | +21.8% |
| 2014 | -$232.54M | -48.8% |
| 2013 | -$156.28M | -1532.2% |
| 2012 | -$9.57M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$6.46M | +40.4% | -136.9% |
| June 30, 2025 | -$2.73M | +82.6% | +81.1% |
| March 31, 2025 | -$14.43M | -28.8% | -33.2% |
| September 30, 2024 | -$10.84M | -23.7% | +31.0% |
| June 30, 2024 | -$15.71M | +2.6% | -40.1% |
| March 31, 2024 | -$11.21M | +55.0% | -27.9% |
| September 30, 2023 | -$8.76M | +38.3% | +45.7% |
| June 30, 2023 | -$16.12M | +30.2% | +35.3% |
- Theravance Biopharma, Inc. showed an increase of +92.3% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Theravance Biopharma, Inc.’s operating income has grown by 62.4% (from -$9.57 million to -$3.60 million).
- The most recent figure is from Theravance Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: